AMERICAN SOCIETY FOR RADIATION ONCOLOGY

FY2026 LHHS Appropriations bill-funding for NIH/NCI Access to radioactive isotopes Support for NRC Commissioner nominee to have medical background Radiation Oncology reimbursement Policy initiatives designed to increase transparency in the prior authorization process Efforts to educate legislators about unintended consequences associated with rate setting for health care services Preserve current training and experience requirements for radiopharmaceuticals Support current NRC medical event reporting regulations and patient safety protocols without additional requirements for extravasations

Oppose CMS's "efficiency adjustment" Support for structural changes that lead to delivering high quality care for patients while increasing efficiencies and promoting Medicare sustainability; oppose radiation oncology benefit managers Support for reforming the way Medicare pays for radiation oncology services by tying payments to quality and value Support for protecting access to care for Medicare patients Oppose physician fee schedule cuts due to clinical labor price updates Support for H.R. 2120 and S. 1031, a bill to modernize radiation oncology reimbursement - The Radiation Oncology Case Rate Value Based Program Act of 2025 Support for H.R. 879, to fix Medicare Physician Fee Schedule's physician payment reimbursement cuts Support H.R.3514, S.1816, the Improving Seniors' Timely Access to Care Act Support for H.R. 6160, Strengthening Medicare for Patients and Providers Act

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Nuclear Regulatory Commission (NRC)

Support legislation to increase the budget for the National Institutes of Health, National Cancer Institute and the Centers for Disease Control and Prevention for FY 2026 and FY2027 Support for increased funding for radiation therapy cooperative groups within the National Cancer Institute Support for the National Institutes of Health to recognize radiation oncology as an individual specialty in reporting systems to create more transparency of federal appropriations Support for ARPA-H to support innovative cancer treatments Support for initiatives to increase diversity in clinical trials Support for DOD lung cancer research program funding Support for report language encouraging NIH to support research into functional radiation medicine